GlobeNewswire Inc.··NaMinerva Neurosciences to Present CNS Pipeline at Stifel Forum Ahead of Key Phase 3 Trial
Minerva Neurosciences CEO to present at Stifel CNS Forum March 18, 2026, as company initiates Phase 3 roluperidone trial for schizophrenia treatment.
NERVbiopharmaceuticalPhase 3 trial